about
Carrier screening for spinal muscular atrophy (SMA) in 107,611 pregnant women during the period 2005-2009: a prospective population-based cohort studySpinal muscular atrophySkeletal muscle training for spinal muscular atrophy type 3Drug treatment for spinal muscular atrophy types II and IIIDrug treatment for spinal muscular atrophy type IDrug treatment for spinal muscular atrophy types II and IIIDrug treatment for spinal muscular atrophy type IDrug treatment for spinal muscular atrophy type IDrug treatment for spinal muscular atrophy types II and IIIClinical and experimental applications of sodium phenylbutyrateiPSCs and small molecules: a reciprocal effort towards better approaches for drug discoveryStem cell transplantation for motor neuron disease: current approaches and future perspectivesSplicing therapy for neuromuscular diseaseSolution structure of the core SMN–Gemin2 complexSystemic restoration of UBA1 ameliorates disease in spinal muscular atrophyA role for SMN exon 7 splicing in the selective vulnerability of motor neurons in spinal muscular atrophyTissue engineering the mechanosensory circuit of the stretch reflex arc: sensory neuron innervation of intrafusal muscle fibers.Sodium vanadate combined with L-ascorbic acid delays disease progression, enhances motor performance, and ameliorates muscle atrophy and weakness in mice with spinal muscular atrophy.Pathological impact of SMN2 mis-splicing in adult SMA miceSomatic Therapy of a Mouse SMA Model with a U7 snRNA Gene Correcting SMN2 SplicingNeuropathology of Amyotrophic Lateral Sclerosis and Its Variants.Development of histone deacetylase inhibitors as therapeutics for neurological diseasePharmacology of a central nervous system delivered 2'-O-methoxyethyl-modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates.Proteomic assessment of a cell model of spinal muscular atrophyPrevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review.A multi-source approach to determine SMA incidence and research ready populationAntisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse modelAssessing spinal muscular atrophy with quantitative ultrasound.Alternative splicing and retinal degenerationTherapeutic developments in spinal muscular atrophy.Inherited neuromuscular disorders: pathway to diagnosis.Activation of the stress proteome as a mechanism for small molecule therapeutics.Permissibility of prenatal diagnosis and abortion for fetuses with severe genetic disorder: type 1 spinal muscular atrophySpinal Muscular Atrophy Therapeutics: Where do we Stand?SMN2 splice modulators enhance U1-pre-mRNA association and rescue SMA mice.Morphological characteristics of motor neurons do not determine their relative susceptibility to degeneration in a mouse model of severe spinal muscular atrophyISS-N1 makes the First FDA-approved Drug for Spinal Muscular Atrophy.Small molecule screen reveals regulation of survival motor neuron protein abundance by Ras proteins.Synthesis and characterization of pseudocantharidins, novel phosphatase modulators that promote the inclusion of exon 7 into the SMN (survival of motoneuron) pre-mRNAA cell system for phenotypic screening of modifiers of SMN2 gene expression and function.
P2860
Q21091059-D0A3F401-32DA-457C-BE60-E83E4CE397EDQ21202863-126DE488-A33F-48F1-9162-0239CCC24F63Q24186074-86BA1B2C-9BF7-4367-91E3-8E70C67B11BAQ24200270-2DD965E7-4FFC-4F4E-B192-1AE5EE06B775Q24200377-F2012D9D-9EB6-49FB-AB59-F71437095B16Q24234414-89788675-25F6-443B-B75B-AC512AC2A27FQ24234523-7709969F-B985-41C7-9B21-DFCC56394409Q24241017-BCAC29BC-F0C3-4E58-B972-82667D543380Q24241759-16D93A10-8348-4574-9ECA-506BDE0C95FCQ24613511-30418B90-7A35-423D-B627-18431C5774F8Q26865055-F8DDBA02-1D2C-40A0-932E-80491F1CA501Q26995278-C4AFAAC0-5942-4B3A-8DD1-D16A37F34A76Q27009581-23D2D083-9FD7-41AF-B074-79BA7E7DE97AQ27679173-05076F95-49FE-4531-8E24-ABEAD6FC71A3Q28279022-644271CB-5802-4754-8DDA-AD29BC97D1AAQ28586960-003B605A-EF4C-483F-B80B-4593A7A31131Q30496625-5F188DF0-FB53-414C-B2D0-6430BB67B1D3Q30540653-BD4E23B7-5AB7-4840-BAD8-351E6601399AQ30551534-5A603275-A6AE-4F67-911B-5C3219985D14Q30828907-F59D567F-FC98-4236-9624-7462CBAE511AQ33361835-1F845CF9-49E1-4A1E-A468-50BB3B9DD6D7Q33670661-F7D17980-186C-4DAB-B90A-2DF0049AF207Q33750824-B978F6D2-D1ED-4C94-955C-2CDC74A86896Q33840295-27D748E8-EFAE-40F8-B711-9C72FF635CCBQ33869164-EB436D93-BA43-44F1-9892-60FCC32D3A35Q33885457-DEAC1103-1146-4A83-B0A2-2B407BB1317AQ34030144-B288CF1C-F999-47C0-A3E6-700A14A5C98DQ34053266-76B4C134-2E85-4939-9CC7-E09E691420DFQ34102442-1A32D15B-B3A4-4233-8592-D87ABF38A5AAQ34156272-9188F8CB-F9CE-4B45-83DA-12200885F8B3Q34229817-B0CA50BA-C7CA-422B-A2CC-AE52FE7D4C2FQ34323595-5F25C96E-65C1-48AD-B4F8-F01AFF30B822Q34363145-5B11B379-9E0A-40C4-BFA3-D07D3B3DD54CQ34460251-EF7B5D07-3F39-4104-A5CC-76C50AD8F3FCQ34478749-DE9F17DD-9077-4CB6-A231-9B5EBB12A217Q34534222-7797FA17-FF91-4D80-8376-CB11D131BF41Q34555103-80EA9D1F-6F76-4AE1-B24B-8F252B3FC569Q34621731-AFE4517D-48FF-41EA-9544-D9FA2147DC86Q34695541-38BB2347-7492-4E63-9EC1-CD1122A4CDA8Q34964785-A0C1ACFA-2409-4DC8-B49B-ADBB86BC4B86
P2860
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Spinal muscular atrophy.
@ast
Spinal muscular atrophy.
@en
type
label
Spinal muscular atrophy.
@ast
Spinal muscular atrophy.
@en
prefLabel
Spinal muscular atrophy.
@ast
Spinal muscular atrophy.
@en
P1433
P1476
Spinal muscular atrophy.
@en
P2093
Ching H Wang
P304
P356
10.1016/S0140-6736(08)60921-6
P407
P577
2008-06-01T00:00:00Z